Human immunodeficiency virus culture positivity as related to participation in clinical trials.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Human immunodeficiency virus culture positivity as related to participation in clinical trials.

Abstr Gen Meet Am Soc Microbiol. 1993;93:434 (abstract no. T-11). Unique Identifier : AIDSLINE ASM93/93291814
Kuk R; Gaur S; Frenkel LD; John JF; Robert Wood Johnson Medical School, New Brunswick, N.J.

Abstract: Viremia with HIV can provide insights into the progression of HIV infection. Our HIV culture laboratory supports an AIDS Clinical Trials Unit (ACTU) but also processes other non-ACTU samples. We questioned if the rates of positive cultures differed between these two groups. Cultures were performed using 6 x 10(6) patient cells cocultured with 6 x 10(6) phytohemagglutinin-stimulated non-HIV infected donor peripheral blood mononuclear cells. Cultures were sampled for p24 antigen twice weekly. The HIV coculture was considered to be positive when two or more HIV p24 antigen determinations were > or = 30 pg/ml. For 135 adult ACTU patients cultured between 1988 clinical and 1992 the positivity rate was 67%. Pediatric patients participating in ACTU protocol 138 and protocol 128 (44 cultures for each protocol) showed a positivity rate of 46% and 77% respectively. For 69 (60 pediatric) non-ACTU patients the positivity rate of 15% was significantly different from adult and pediatric clinical trials groups (p < 0.001). We conclude that in these patient populations the inclusion in an ACTU study was associated with higher rates of HIV-positive cultures.

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*MICROBIOLOGY Adult Cells, Cultured Child Clinical Trials/*METHODS Human HIV/*GROWTH & DEVELOPMENT HIV Core Protein p24/ANALYSIS HIV Seropositivity/IMMUNOLOGY/*MICROBIOLOGY Lymphocyte Transformation Lymphocytes/IMMUNOLOGY/*MICROBIOLOGY ABSTRACT
930930
M9391157

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .